Business
Picard Medical Reports Full Year 2025 Financial Results
Revenue Growth and Continued Adoption of SynCardia Total Artificial HeartTUCSON, Ariz., March 25, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today reported financial results for the year ended December 31, 2025. The year reflected a transformational period for the Company highlighted by revenue growth, improved operat
About this update from Picard Medical, Inc.
[{"type":"image","alt":"Picard Medical, Inc.","displaySize":"","headline":null,"caption":"Picard Medical, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":75,"url":"https://media.zenfs.com/en/globenewswire.com/4e25733b249cfcdd029f5354275c291a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/MiFgFhEV9BOpmHkrZOmKRQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNQ--/https://media.zenfs.com/en/globenewswire.com/4e25733b249cfcdd029f5354275c291a","width":300,"height":75}},"lazy":false},{"type":"text","content":"Revenue Growth and Continued Adoption of SynCardia Total Artificial Heart","length":73,"tagName":"p"},{"type":"text","content":"TUCSON, Ariz., March 25, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first total artificial heart approved by both the U.S. FDA and Health Canada, today reported financial results for the year ended December 31, 2025. The year reflected a transformational period for the Company highlighted by revenue growth, improved operating performance, and a strengthened balance sheet following the successful completion of the Company public listing and related capital raises.","length":570,"tagName":"p"},{"type":"text","content":"Key Financial Highlights","length":24,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Revenue of $4.9 million, an increase of 12.5 percent compared to 2024","length":69,"tagName":"p"}]},{"val":[{"type":"text","content":"Product revenue of $4.7 million representing 96 percent of total revenue","length":72,"tagName":"p"}]},{"val":[{"type":"text","content":"Gross margin was (4.1 percent) compared to (2.6 percent) in 2024","length":64,"tagName":"p"}]},{"val":[{"type":"text","content":"Operating loss was $(13.3) million compared to $(13.7) million in 2024","length":70,"tagName":"p"}]},{"val":[{"type":"text","content":"Net loss was $(27.0) million compared to $(21.1) million in 2024","length":64,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash, cash equivalents and restricted cash of $11.5 million at year end compared to $0.1 million (December 31, 2024)","length":116,"tagName":"p"}]},{"val":[{"type":"text","content":"$17.4 million net proceeds raised from equity financings and $9.7 million net proceeds from debt financing during 2025","length":118,"tag...